← board
CNSP
CNS Pharmaceuticals, Inc.distress 10/10 · high distress / dilution risk$5.64-3%today-48% from 52w high
Oncology 1
Lead: Glioblastoma Multiforme
Revenue
pre-revenue
Liquidity
$3M
Runway
0.2 yrs
Shares 1y
+154%
Price & events
-9.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
+19.0%
1W
+31.5%
1M
+128.3%
3M
-6.6%
6M
-31.3%
1Y
-99.1%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $8.24M
- Volume
- 1.03K
- 52 Week Range
- $2.13 – $10.75
- Total Shares
- 1.46M
- Float Shares
- 1.45M
- Short %
- 2.50%
- % Held by Insiders
- 0.49%
- % Held by Institutions
- 12.51%
- RVOL
- 0.08x
- Beta
- 1.02
Pipeline stages · 1 programs
Berubicin, Lomustine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04-27 | Phase 2 | Berubicin, Lomustineorphanfast track | Glioblastoma Multiforme, Adult | 252 | active not recruiting |
Catalyst news & presentations · 2
- first half of 2025readoutPhase 3Berubicin · Primary analysis data from potentially pivotal Phase 3 trialSEC 8-K
- 2024-10-30fda agreementNasdaq panel granted temporary exception until March 11, 2025 to regain minimum bid price compliance.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-12Maxim GroupHold → Buy
- 2025-03-25Maxim GroupBuy → Hold
Competitors — Glioblastoma Multiforme
Recent news
- 2026-07-02Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
- 2026-06-30Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Sarepta Therapeutics
- 2026-06-28Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
- 2026-06-26CNS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CNSP) - TradingView
- 2026-06-25CNSP Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25CNS Pharmaceuticals (CNSP) Slides 4.7% as Biotech Sentiment Wavers; Support at $3.84 in Focus - Swing Entry Signals - dars.gov.et
- 2026-06-18CNS Pharmaceuticals Inc (CNSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
- 2026-06-18CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.